CROX DEADLINE NOTICE: BFA Law Alerts Crocs, Inc. Investors that Lost Money to Contact the Firm by the March 24 Class Action Deadline
New York, New York-- (Newsfile Corp. - February 25, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Crocs, Inc. (NASDAQ: CROX) and ...
EQS-News: Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®
EQS-News: Formycon AG / Key word (s): Regulatory Approval Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® ...
PharmiWeb8h
Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®
Regulatory ApprovalFormycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® 25.02.2025 / 06:30 CET/CESTThe issuer is solely ...
Teva and Alvotech launch ustekinumab biosimilar injection in US
Teva Pharmaceuticals and Alvotech have announced the US launch of the Selarsdi (ustekinumab-aekn) injection, a biosimilar to ...
Sanofi and Teva report new outcomes from Phase IIb trial of duvakitug
Sanofi and Teva Pharmaceuticals have reported new outcomes from the randomised Phase IIb RELIEVE UCCD trial of human ...
Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide
Pursuing the world's first-ever orally-dosed liraglutide KELOWNA, BC / / February 20, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW ...
Kauppalehti5d
Putting Patients First: Why Europe Must Act to Protect Access To Medicines
A diversified supply of critical generic medicines from multiple manufacturers is required to ensure that healthcare systems can meet the needs of their patients. The research shows that for most ...
Teva Pharmaceutical Industries Ltd: Putting Patients First: Why Europe Must Act to Protect Access To Medicines
New research by Teva Pharmaceuticals Europe shows that 46% of generic medicines from the EU Critical List of Medicines are supplied by only one provider. This ...
Billionaire Stanley Druckenmiller Dumped Duquesne's Entire Stake in Broadcom and Bought One of Wall Street's Hottest Drug Stocks Hand Over Fist
Duquesne Family Office's billionaire chief shed a trillion-dollar artificial intelligence (AI) stock in favor of a ...
Drug Store News5d
Generic drug suppliers weigh in on predictable, unpredictable category impact
Biosimilars have also made inroads among generic suppliers. But development is lengthy and expensive. McKinsey estimates that it costs $100 to $300 million to develop a biosimilar and that it takes ...
Managed Healthcare Executive6d
FDA Accepts Alvotech/Teva’s Application for Eylea Biosimilar
So far, five biosimilars that reference Eylea 2 mg have been approved by the FDA. Alvotech/Teva expect to regulatory approval ...
Contract Pharma6d
FDA Accepts Alvotech’s Eylea Biosimilar for Review
The U.S. Food and Drug Administration (FDA) has approved for review a Biologics License Application (BLA) for AVT06, Alvotech ...